Amgen, SoftBank and Alexandria Real Estate Equities helped the neurodegenerative disease drug developer publicly launch with $500m in funding.

Neumora Therapeutics, a US-based developer of brain disease treatments, has collected over $500m in a series A round that included $100m from pharmaceutical firm Amgen. Internet and telecommunications conglomerate SoftBank’s Vision Fund 2 also took part in the round, as did life sciences real estate investment trust Alexandria Real Estate Equities, through venture capital arm…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.